TABLE 1.
Demographic and Clinical Characteristics of Patients With IBD and Control Patients
| IBD (n = 21) | Control (n = 22) | P | |
|---|---|---|---|
| Age, y (mean ± SD)* | 43 ± 16 | 47 ± 14 | 0.319 |
| Gender, female/male, n (%)† | 7/14 (33/67) | 8/14 (36/64) | 1.000 |
| BMI, kg/m2 (mean ± SD)* | 25 ± 5 | 27 ± 4 | 0.072 |
| Smoking/snuff habits, n (%)† | 0.755 | ||
| Active | 8 (38) | 7 (32) | |
| Never/former | 13 (62) | 15 (68) | |
| IBD diagnosis, n (%) | |||
| CD | 12 (57) | - | |
| UC | 9 (43) | - | |
| Disease duration, y (mean ± SD) | 3 ± 5 | - | |
| Disease location, CD, n (%)‡ | |||
| Ileum (L1) | 3 (25) | - | |
| Colon (L2) | 6 (50) | - | |
| Ileocolic (L3) | 3 (25) | - | |
| Upper GI (L4) | 0 (0) | - | |
| Disease extent, UC, n (%)‡ | |||
| Proctitis (E1) | 0 (0) | - | |
| Left-sided (E2) | 4 (44) | - | |
| Extensive (E3) | 4 (44) | - | |
| Unknown | 1 (1) | - | |
| Abdominal surgery, n (%) | |||
| Yes | 4 (19) | - | |
| No | 17 (81) | - | |
| Medical treatment, n (%) | |||
| Glucocorticoids | 13 (62) | - | |
| Anti-TNFs/biologics | 4 (19) | - | |
| Thiopurines | 4 (19) | - | |
| 5-ASAs | 3 (14) | - | |
| No treatment | 2 (10) | - | |
| SES-CD (mean ± SD) | 11 ± 5 | - | |
| UCEIS (mean ± SD) | 2 ± 1 | - | |
| Total protein, mg/mL (mean ± SD)* | |||
| Unstimulated saliva | 1.1 ± 0.5 | 0.9 ± 0.3 | 0.392 |
| Stimulated saliva | 0.9 ± 0.3 | 0.8 ± 0.3 | 0.796 |
| Salivary flow, mL/min (mean ± SD)* | |||
| Unstimulated saliva | 0.4 ± 0.2 | 0.3 ± 0.2 | 0.067 |
| Stimulated saliva | 1.8 ± 1.0 | 1.1 ± 0.7 | 0.006 |
*Mann-Whitney U test, control patients vs patients with IBD.
†χ 2 test, control patients vs patients with IBD.
‡According to the Montreal Index.
5-ASA indicates 5-aminosalicylic acid/mesalazine; SD, standard deviation.